Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Pertussis-Pipeline Review, H1 2015

Pertussis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Pertussis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pertussis-Pipeline Review, H1 2015', provides an overview of the Pertussis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pertussis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pertussis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Pertussis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pertussis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pertussis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pertussis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pertussis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pertussis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Pertussis Overview 10

Therapeutics Development 11

Pipeline Products for Pertussis-Overview 11

Pipeline Products for Pertussis-Comparative Analysis 12

Pertussis-Therapeutics under Development by Companies 13

Pertussis-Therapeutics under Investigation by Universities/Institutes 16

Pertussis-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Pertussis-Products under Development by Companies 21

Pertussis-Products under Investigation by Universities/Institutes 23

Pertussis-Companies Involved in Therapeutics Development 24

Beijing Minhai Biotechnology Co., Ltd 24

Beijing Tiantan Biological Products Co., Ltd. 25

Bharat Biotech International Limited 26

Biological E. Limited 27

Daiichi Sankyo Company, Limited 28

DBV Technologies S.A. 29

Green Cross Corporation 30

Indian Immunologicals Limited 31

LG Life Sciences, Ltd. 32

NanoBio Corporation 33

Novartis AG 34

Panacea Biotec Limited 35

Sanofi 36

Sanofi Pasteur SA 37

Serum Institute of India Limited 38

Sinovac Biotech Ltd. 39

Synthetic Biologics, Inc. 40

Takeda Pharmaceutical Company Limited 41

Zydus Cadila Healthcare Limited 42

Pertussis-Therapeutics Assessment 43

Assessment by Monotherapy Products 43

Assessment by Combination Products 44

Assessment by Target 45

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

(diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2 ,3)) vaccine-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

diphtheria + pertussis + tetanus vaccine-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

diphtheria + pertussis + tetanus vaccine-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

diphtheria + tetanus + pertussis (acellular) vaccine-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

diphtheria + tetanus + pertussis (acellular) vaccine-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

diphtheria + tetanus+ pertussis vaccine-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

diptheria + tetanus + pertussis (whole-cell) vaccine-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

DTaP Vaccine-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

GC-3111A-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

pertussis (acellular) vaccine-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

pertussis (acellular) vaccine-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

pertussis (whole-cell) vaccine-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

pertussis + hepatitis B vaccine-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

pertussis vaccine-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

pertussis vaccine-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

pertussis vaccine-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

pertussis vaccine-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

pertussis vaccine-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Recombinant BCG-Pertussis Vaccine-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

SYN-005-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

TAK-361S-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

tetanus + diphtheria + pertussis (acellular) vaccine-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

VN-0103-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Pertussis-Recent Pipeline Updates 86

Pertussis-Dormant Projects 88

Pertussis-Product Development Milestones 90

Featured News & Press Releases 90

Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 90

Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 90

Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) 91

Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 92

Apr 23, 2014: Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic 92

Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age 93

Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 94

Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 95

Dec 20, 2012: Synthetic Biologics And Intrexon Initiate Development Of Monoclonal Antibodies For Whooping Cough 96

Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 96

Appendix 98

Methodology 98

Coverage 98

Secondary Research 98

Primary Research 98

Expert Panel Validation 98

Contact Us 99

Disclaimer 99

List of Tables

Number of Products under Development for Pertussis, H1 2015 11

Number of Products under Development for Pertussis-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Development, H1 2015 19

Comparative Analysis by Unknown Stage Development, H1 2015 20

Products under Development by Companies, H1 2015 21

Products under Development by Companies, H1 2015 (Contd..1) 22

Products under Investigation by Universities/Institutes, H1 2015 23

Pertussis-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 24

Pertussis-Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2015 25

Pertussis-Pipeline by Bharat Biotech International Limited, H1 2015 26

Pertussis-Pipeline by Biological E. Limited, H1 2015 27

Pertussis-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 28

Pertussis-Pipeline by DBV Technologies S.A., H1 2015 29

Pertussis-Pipeline by Green Cross Corporation, H1 2015 30

Pertussis-Pipeline by Indian Immunologicals Limited, H1 2015 31

Pertussis-Pipeline by LG Life Sciences, Ltd., H1 2015 32

Pertussis-Pipeline by NanoBio Corporation, H1 2015 33

Pertussis-Pipeline by Novartis AG, H1 2015 34

Pertussis-Pipeline by Panacea Biotec Limited, H1 2015 35

Pertussis-Pipeline by Sanofi, H1 2015 36

Pertussis-Pipeline by Sanofi Pasteur SA, H1 2015 37

Pertussis-Pipeline by Serum Institute of India Limited, H1 2015 38

Pertussis-Pipeline by Sinovac Biotech Ltd., H1 2015 39

Pertussis-Pipeline by Synthetic Biologics, Inc., H1 2015 40

Pertussis-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 41

Pertussis-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 42

Assessment by Monotherapy Products, H1 2015 43

Assessment by Combination Products, H1 2015 44

Number of Products by Stage and Target, H1 2015 46

Number of Products by Stage and Route of Administration, H1 2015 48

Number of Products by Stage and Molecule Type, H1 2015 50

Pertussis Therapeutics-Recent Pipeline Updates, H1 2015 86

Pertussis-Dormant Projects, H1 2015 88

Pertussis-Dormant Projects (Contd..1), H1 2015 89

List of Figures

Number of Products under Development for Pertussis, H1 2015 11

Number of Products under Development for Pertussis-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Products, H1 2015 19

Assessment by Monotherapy Products, H1 2015 43

Assessment by Combination Products, H1 2015 44

Number of Products by Top 10 Targets, H1 2015 45

Number of Products by Stage and Top 10 Targets, H1 2015 46

Number of Products by Top 10 Routes of Administration, H1 2015 47

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 48

Number of Products by Top 10 Molecule Types, H1 2015 49

Number of Products by Stage and Top 10 Molecule Types, H1 2015 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Beijing Minhai Biotechnology Co., Ltd

Beijing Tiantan Biological Products Co., Ltd.

Bharat Biotech International Limited

Biological E. Limited

Daiichi Sankyo Company, Limited

DBV Technologies S.A.

Green Cross Corporation

Indian Immunologicals Limited

LG Life Sciences, Ltd.

NanoBio Corporation

Novartis AG

Panacea Biotec Limited

Sanofi

Sanofi Pasteur SA

Serum Institute of India Limited

Sinovac Biotech Ltd.

Synthetic Biologics, Inc.

Takeda Pharmaceutical Company Limited

Zydus Cadila Healthcare Limited

Pertussis Therapeutic Products under Development, Key Players in Pertussis Therapeutics, Pertussis Pipeline Overview, Pertussis Pipeline, Pertussis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com